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Serotonergic neurons in the dorsal raphe nucleus (DRN) are involved in the control of sleep-wake states. Our
previous studies have indicated that calcium (Ca2+) modulation in the DRN plays an important role in rapid-eye-
movement sleep (REMS) and non-REMS (NREMS) regulation during pentobarbital hypnosis. The present study
investigated the effects of Ca2+ in the DRN on sleep-wake regulation and the related neuronal mechanism in freely
moving rats. Our results showed that microinjection of CaCl2 (25 or 50 nmol) in the DRN promoted wakefulness
and suppressed NREMS including slow wave sleep and REMS in freely moving rats. Application of CaCl2 (25 or
50 nmol) in the DRN significantly increased serotonin in the DRN and hypothalamus, and noradrenaline in the locus
coeruleus and hypothalamus. Immunohistochemistry study indicated that application of CaCl2 (25 or 50 nmol) in
the DRN significantly increased c-Fos expression ratio in wake-promoting neurons including serotonergic neurons
in the DRN, noradrenergic neurons in the locus coeruleus, and orxinergic neurons in the perifornical nucleus, but
decreased c-Fos expression ratio of GABAergic sleep-promoting neurons in the ventrolateral preoptic nucleus.
These results suggest that Ca2+ in the DRN exert arousal effects via up-regulating serotonergic functions in the
endogenous sleep-wake regulating pathways.
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Dorsal raphe nucleus (DRN) provides the majority of
serotonin (5-HT) throughout the central nervous sys-
tem, including the cerebral cortex, hypothalamus and
brain stem [1]. Serotonergic neurons in the DRN play an
important role in sleep-wake regulation [2, 3]. Most of
the serotonergic neurons in the DRN fire regularly at a
slow rate during wakefulness, fire considerably less dur-
ing non-rapid eye movement sleep (NREMS) and even
cease firing during rapid eye movement sleep (REMS)
[4, 5]. 5-HT release in many brain regions occurs pre-
dominantly during wakefulness, and diminishes at its
lowest level during REMS [6]. In the endogenous sleep-
wake regulating pathways, the DRN promotes wakeful-
ness via excitatory projections to the cerebral cortex and* Correspondence: zhyh@hsc.pku.edu.cn
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projections to sleep-promoting nuclei [1–3, 7].
Calcium (Ca2+) and Ca2+ channels express widely
throughout the central nervous system and modulate
neurotransmitter release and neuron excitability [8, 9].
Numerous in vitro and in vivo studies have supported
that the Ca2+ current of the serotonergic neurons in the
DRN is of prime importance in maintaining 5-HT levels
throughout the brain [10–12].
Our previous study indicated that Ca2+ modulation
in the DRN plays an important role in sleep regula-
tion [13, 14]. We found that up-regulation of Ca2+
function in the DRN could reduce NREMS and
REMS, but down-regulation of Ca2+ function in the
DRN could promote NREMS, especially slow wave
sleep (SWS) in pentobarbital-treated rats [13]. How-
ever the precise mechanism has not been certified
yet. The present study investigated the neuroanatom-
ical mechanism of the arousal effects of Ca2+ in thele is distributed under the terms of the Creative Commons Attribution 4.0
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and monitored sleep-wake behavior in freely moving
rats for 6 hours. Then, we measured monoamine neu-
rotransmitters and the neuronal activity in the en-
dogenous sleep-wake regulating brain areas 3 h after
CaCl2 administration.
Results
Effects of CaCl2 microinjection in the DRN on sleep
parameters
Sleep-wake behavior was monitored for 6 h (09:00–
15:00) after CaCL2 (25 or 50 nmol) was microinjected inFig. 1 Microinjection of CaCl2 (25 or 50 nmol) into the dorsal raphe nucleu
(TS), non-rapid eye movement sleep (NREMS), light sleep (LS), slow wave sl
relative to TS (LS%), percentage of SWS relative to TS (SWS%) and percenta
W, TS, NREMS, LS, SWS and REMS episodes; (e) Time spent in TS per 1
and **p < 0.01 vs Vehicle (Student-Newman-Keuls test)the DRN. Microinjection of CaCl2 (25 or 50 nmol) in the
DRN significantly increased wakefulness (W, F2, 27 = 10.44,
p < 0.01, Fig. 1a) and the mean duration of W at dose of
50 nmol (F2, 27 = 6.75, p < 0.01, Fig. 1d). Microinjection of
CaCl2 (25 or 50 nmol) in the DRN significantly decreased
total sleep (TS) time (F2, 27 = 10.44, p < 0.01, Fig. 1a) com-
pared with the vehicle group. Sleep latency (SL) was not
influenced by intra-DRN Ca2+ administration (Fig. 1a).
The sleep episode analysis revealed that the CaCl2
(25 or 50 nmol) microinjection in the DRN signifi-
cantly reduced NREMS time (F2, 27 = 9.53, p < 0.01,
Fig. 1a). Microinjection of CaCl2 (25 or 50 nmol) ins (DRN) decreased sleep time in rats. (a) Wakefulness (W), total sleep
eep (SWS) and rapid eye movement sleep (REMS); (b) Percentage of LS
ge of REMS relative to TS (REMS%); (c, d) Bouts and mean duration of
h (n = 10/group). Data are represented as mean ± SEM, *p < 0.05
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p < 0.05, Fig. 1a) and LS bouts (F2, 27 = 8.74, p < 0.01,
Fig. 1c). Microinjection of CaCl2 (25 or 50 nmol) in
the DRN decreased SWS time (F2, 27 = 7.55, p < 0.01,
Fig. 1a) and SWS bouts (F2, 27 = 9.10, p < 0.01, Fig. 1c).
Microinjection of the high dose of CaCl2 (50 nmol)
significantly decreased REMS time (F2, 27 = 3.67, p < 0.05,
Fig. 1a) and REMS bouts (F2, 27 = 4.15, p < 0.05, Fig. 1c).
Microinjection of CaCl2 (25 or 50 nmol) in the DRN sig-
nificantly increased the percentage of LS relative to TS
(LS%, F2, 27 = 7.57, p < 0.01, Fig. 1b) and decreased the
percentage of SWS relative to TS (SWS%, F2, 27 = 5.65,
p < 0.01, Fig. 1b). The percentage of REMS relative to
TS (REMS%) was not influenced by intra-DRN Ca2+
administration (Fig. 1b).
TS time was analyzed in 1-h blocks after vehicle or
CaCl2 (25 or 50 nmol) was microinjected into the DRN.
Results indicated TS time was significantly reduced from
the 3rd 1-h period (S3) to the 6th 1-h period (S6) in
CaCl2 groups (25 or 50 nmol) compared with vehicle
group (S3, F2, 27 = 6.41, p < 0.01; S4, F2, 27 = 4.68, p < 0.05;
S5, F2, 27 = 4.89, p < 0.05; S6, F2, 27 = 6.62, p < 0.01, Fig. 1e).
Effects of CaCl2 microinjection in the DRN on monoamine
neurotransmitters
Application of CaCl2 in the DRN significantly decreased
sleep time. Based on the important effects of serotoner-
gic neurons in the DRN on sleep regulation, we hypoth-
esized that the arousal effects of CaCl2 in the DRN
might be related to the serotonergic system. Seroto-
nergic projections from the DRN to the prefrontal
cortex, hypothalamus and LC are crucial in the sleep-
wake cycle [1, 15–17]. Noradrenaline (NE), serotonin
(5-HT) and 5-hydroxyindoleacetic acid (5-HIAA, final
metabolite of 5-HT) in the DRN, prefrontal cortex,
hypothalamus and LC were detected 3 h after intra-
DRN CaCl2 administration.
Microinjection of CaCl2 (25 or 50 nmol) in the DRN
significantly increased 5-HT (F2, 18 = 5.03, p < 0.05) and
5-HIAA (F2, 18 = 5.09, p < 0.05) in the DRN (Fig. 2a),
and NE (F2, 15 = 15.96, p < 0.01) and 5-HT (F2, 15 = 5.17,
p < 0.05) in the hypothalamus (Fig. 2c). Microinjection
of the high dose of CaCl2 (50 nmol) significantly in-
creased NE in the LC (F2, 18 = 5.56, p < 0.05, Fig. 2d).
Monoamine levels in the prefrontal cortex were not in-
fluenced by intra-DRN CaCl2 (25 or 50 nmol) adminis-
tration (Fig. 2b).
The DRN has the highest density of serotonergic neu-
rons in the brain. 5-HT and 5-HIAA in the DRN were
increased followed by intra-DRN CaCl2 administration.
It might be direct effects of Ca2+ on serotonergic system.
However the effects of intra-DRN CaCl2 administration
on monoamine levels in the hypothalamus and LC might
be occurred secondary to the up-regulating effects ofCa2+ on serotonergic neurons. Pearson’s correlation ana-
lysis indicated that the level of 5-HT in the DRN was
positively correlated with the level of 5-HT in the hypo-
thalamus (R = 0.617, p < 0.01, Fig. 2e) and the level of NE
in the LC (R = 0.555, p < 0.05, Fig. 2f ).
Effects of CaCl2 microinjection in the DRN on neuronal
activity in sleep-wake regulating nucleus
Microinjection of CaCl2 (25 or 50 nmol) in the DRN
suppressed sleep and augmented serotonergic functions
in sleep-wake regulating brain areas including DRN, LC
and hypothalamus. GABAergic neurons in the ventrolat-
eral preoptic nucleus (VLPO) [18] and histaminergic
neurons in the TMN [19] and orexinergic neurons in the
perifornical nucleus (Pef ) [20] are the most crucial com-
ponent in the hypothalamic sleep regulation [21]. We
performed double-staining immunofluorescence in the
DRN, VLPO, TMN, Pef and LC to detect c-Fos expres-
sion ratio in specific neurons after 3 h intra-DRN CaCl2
application. c-Fos expression is often considered as an
index of neuronal activation.
Microinjection of CaCl2 (25 or 50 nmol) in the DRN
significantly increased c-Fos positive ratio of serotoner-
gic neurons in the DRN (F2, 14 = 13.65, p < 0.01, Fig. 3a)
and c-Fos positive ratio of orexinergic neurons in the Pef
(F2, 14 = 25.02, p < 0.01, Fig. 3c), as well as c-Fos positive
ratio of noradrenergic neurons in the LC (F2, 18 = 34.20,
p < 0.01, Fig. 3e). Microinjection of CaCl2 (25 or 50 nmol)
in the DRN significantly decrease c-Fos positive ratio of
GABAergic neurons in the VLPO (F2, 24 = 34.64, p < 0.01,
Fig. 3b). c-Fos positive ratio of histaminergic neurons in
the TMN was not influenced by intra-DRN CaCl2 (25 or
50 nmol) administration (Fig. 3d).
Discussion
CaCl2 (25 or 50 nmol) was applied in the DRN at
daytime, causing the following principal findings: (i) W
time significantly increased, and this effect could attri-
bute to increases in mean duration of episodes (Fig. 1),
and (ii) LS, SWS and REMS significantly decreased, and
this effect could attribute to increases in bouts of epi-
sodes (Fig. 1), and (iii) 5-HT in the DRN and hypothal-
amus, and NE in the LC and hypothalamus significantly
increased (Fig. 2), and (iv) c-Fos expression ratio of spe-
cific neurons in wake-promoting brain areas (DRN, LC
and Pef ) significantly increased, but c-Fos expression ra-
tio of GABAergic sleep-promoting neurons in the VLPO
significantly decreased (Fig. 3). These results implied
that Ca2+ in the DRN exerted the arousal effects via up-
regulating serotonergic functions in endogenous sleep-
wake regulating pathway.
Serotonergic neurons in the DRN promote wakeful-
ness and inhibit NREMS and REMS [2, 22]. Serotonergic
REM-off neurons in the DRN play suppressive roles in
Fig. 2 Microinjection of CaCl2 (25 or 50 nmol) into the dorsal raphe nucleus (DRN) increased monoamine neurotransmitters. Norepinephrine (NE),
serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) levels in the dorsal raphe nucleus (a), prefrontal cortex (b), hypothalamus (c), and locus
coeruleus (d) were analyzed. The relationship between the 5-HT in the DRN and 5-HT in the hypothalamus (e) or NE in the LC (f) were analyzed
(n = 6 ~ 8/group). Data are calculated as ng/g protein and expressed as mean ± SEM, *p < 0.05 and **p < 0.01 vs Vehicle (Student-Newman-Keuls
test and Pearson’s correlation analysis)
Cui et al. Molecular Brain  (2016) 9:71 Page 4 of 10REMS genesis by inhibiting cholinergic REM-on neu-
rons [3, 7]. DRN serotonergic neurons facilitate the con-
solidation of NREMS by receiving the GABAergic
inhibitory inputs from the VLPO, which in turn disin-
hibits their effects on VLPO [23]. The activity of seroto-
nergic neurons in DRN was modulated by excitatory or
inhibitory neurotransmitter and/or neuromodulators
from non-serotonergic neurons in the DRN and the syn-
aptic projections derived from all over the brains, which
is currently accepted as a crucial component of sleep-
wake regulation [2].Both the Ca2+-dependent release of neurotransmitters
from the presynaptic membrane and the Ca2+-mediating
cellular signal transduction in post-synaptic neurons are
important mechanisms underneath neurons connection
throughout the brain. It has been proved that the orexi-
nergic [8] and glutamatergic [24, 25] exciting signals to
the DRN serotonergic neurons were medicated by eleva-
tion of Ca2+ influx. The research from Barbosa et al. in-
dicates that Ca2+ influx is essential for the activation
of tryptophan hydroxylase, the rate-limiting enzyme
in the 5-HT synthesis, and potentially increases 5-HT
Fig. 3 (See legend on next page.)
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Fig. 3 Microinjection of CaCl2 (25 or 50 nmol) into the dorsal raphe nucleus (DRN) affected neuronal activity in sleep-wake regulating nucleus.
The nucleus-specific neurotransmitter markers were labeled by green, c-Fos was labeled by red and DAPI was labeled by blue. (a) In the DRN,
nucleus-specific neurotransmitter marker is tryptophan hydroxylase and tryptophan hydroxylase (+) neurons indicate serotonergic neurons. (b) In
the ventrolateral preoptic nucleus (VLPO), nucleus-specific neurotransmitter marker is glutamic acid decarboxylase and glutamic acid decarboxylase (+)
neurons indicate GABAergic neurons. (c) In the perifornical nucleus (Pef), nucleus-specific neurotransmitter marker is orexin. (d) In tuberomammillary
nucleus (TMN), nucleus-specific neurotransmitter marker is adenosine deaminase and adenosine deaminase (+) neurons indicate histaminergic
neurons. (e) In the locus coeruleus (LC), nucleus-specific neurotransmitter marker is tyrosine hydroxylase and tyrosine hydroxylase (+) neurons indicate
noradrenergic neurons. Yellow arrows indicate c-Fos (−)-nucleus-specific neurotransmitter marker (+) neurons. White arrows indicate c-Fos
(+)-nucleus-specific neurotransmitter marker (+) neurons. c-Fos (+) ratio in the specific neurons was counted (n = 5 ~ 9/group). Data are
represented as mean ± SEM, *p < 0.05 and **p < 0.01 vs Vehicle (Student-Newman-Keuls test)
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evidence indicating that intra-DRN Ca2+ application
could potentiate serotonergic system function. The
present study shows that intra-DRN Ca2+ application
increase W and suppress NREMS and REMS (Fig. 1),
which is accordance with arousal effects of the DRN
serotonergic neurons on sleep-wake regulation [2, 3].
We also detected significant increases in 5-HT and
serotonergic neurons activity in the DRN followed by
intra-DRN Ca2+ application. These results indicate that
the arousal effects of Ca2+ in the DRN might be related to
its up-regulating effects on serotonergic function.
Our previous research indicated that the arousal ef-
fects of Ca2+ in DRN were associated with activation of
protein kinase C (PKC) and calmodulin-dependent
kinase II (CaMKII) signaling pathway, since the arousal
effects of Ca2+ were respectively abolished by PKC
inhibitor, chelerythrine chloride, or CaMKII inhibitor,
KN-93 [27, 28]. Numerous studies suggest that the Ca2+
induced PKC or CaMKII signaling cascade can potenti-
ate the function of the serotonergic system. Based on
the present results and previous studies, we hypothe-
sized that the application of Ca2+ might potentiate sero-
tonergic function by the activation of PKC and/or
CaMKII mediated signal transduction in the DRN. Fur-
thermore, we interestingly noticed that the potential
effect of Ca2+ on serotonergic function did not only
restricted in the DRN, but also stretched to other en-
dogenous sleep-wake regulating pathway.
The sleep-wake regulating pathway in the brain is
based on alternating excitation between sleep-promoting
neurons and wake-promoting neurons [21, 29]. The
sleep-promoting GABAergic neurons in the VLPO pro-
ject to the wake-promoting neurons including serotoner-
gic neurons in the DRN, noradrenergic neurons in the
LC and histaminergic neurons in the TMN, then inhibit
their release of neurotransmitters into the cortex and
disinhibit their inhibitory effects on the VLPO, which
facilitates the consolidation of sleep [21, 29]. The direct
mutual inhibition between the VLPO and the monoam-
inergic cell groups forms a classic flip-flop switch,
which produces sharp transitions between sleep andwakefulness. Orexinergic neurons reinforce the arousal
systems, which benefit to stabilize the flip-flop switch, like
a ‘finger’ on the switch that might prevent unwanted tran-
sitions into sleep [21, 29, 30]. The present study shows
that the increases in monoamine levels in the hypothal-
amus and LC followed by intra-DRN Ca2+ application
were positively correlated with the level of 5-HT in the
DRN (Fig. 2). Furthermore, intra-DRN Ca2+ application
not only significantly increased wake-promoting neurons
activity in the DRN, Pef and LC, but also significantly de-
creased sleep-promoting GABAergic neurons activity in
the VLPO (Fig. 3). The changes of neurotransmitters and
neuronal activity in endogenous sleep-wake regulating
pathway followed by intra-DRN Ca2+ application are fa-
cilitate to wakefulness, which are accordance with the
arousal effects of Ca2+ (Fig. 4).
5-HT and the serotonergic neurons activity were in-
creased followed by microinjection of CaCl2 in the DRN.
It might be direct effects of Ca2+ on serotonergic system.
However, the changes of monoamine levels and neuronal
activity in other endogenous sleep-wake regulating path-
way might be occurred secondary to the up-regulating
effects of Ca2+ on serotonergic system. Serotonergic
neural projection from the DRN and serotonergic recep-
tors are detected in the hypothalamus and LC [31–33],
which implies the neurons in the hypothalamus and LC
might be modulated by 5-HT. Electrical or chemical
stimulation of the DRN led to an increased release of 5-
HT in the hypothalamus and LC [34, 35] Pharmaco-
logical study shows that the agonists of 5HT1A or 5HT3
receptor respectively increase noradrenergic activity in
the LC [36, 37]. GABAergic sleep-promoting neurons in
the VLPO are inhibited by 5-HT and NE [38]. These
research provide persuasive evidence supporting the sec-
ondary effect of Ca2+, since c-Fos expressions in the nor-
adrenergic neurons in the LC were increased and c-Fos
expression in the GABAergic neurons in the VLPO were
decreased followed by up-regulating effects of Ca2+ on
serotonergic system. Research from Tabuchi et al. indi-
cated that enhancement of inhibitory serotonergic input
to orexinergic neurons via 5HT1A receptor caused frag-
mentation of wakefulness [39]. Present study shows that
Fig. 4 The presumed neuroanatomical mechanism of the arousal effects of Ca2+ in the dorsal raphe nucleus (DRN). Microinjection of CaCl2 in the
DRN promotes wakefulness and suppresses sleep. By activating protein kinase C (PKC) or calmodulin-dependent kinase II (CaMKII) mediated signal
transduction, the intra-DRN application of Ca2+ might potentiate serotonin (5-HT) synthesis, which up-regulates serotonergic functions in endogenous
sleep-wake regulating pathway, causing decreased GABAergic neurons activity in the ventrolateral preoptic nucleus (VLPO), increased orexinergic
neurons activity in the perifornical nucleus (Pef) and increased noradrenergic neurons activity in the locus coeruleus (LC)
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wakefulness, which might be related to the increase
of c-Fos expression in orexinergic neurons. However,
it seems that the positive effect on orexinergic neu-
rons induced by Ca2+ administration was not medi-
cated by 5HT1A receptor at least, and other serotonergic
receptors and neuromodulators should be considerate.
The present study, together with our previous reports
[27, 28] demonstrate the application of Ca2+ in the DRN
promotes wakefulness and suppresses both NREMS and
REMS in freely moving rats. By activating PKC or
CaMKII mediated signal transduction, the intra-DRN
application of Ca2+ might potentiate 5-HT synthesis,
which up-regulates serotonergic functions in endogen-
ous sleep-wake regulating pathway including DRN,
LC, VLPO and Pef (Fig. 4). These findings are critical
for our complete understanding of the basic mecha-
nisms of sleep-wake regulation.
Methods
Animals
Male Sprague–Dawley rats (220–240 g, Grade I, pur-
chased from the Animal Center of Peking University,
Beijing, China) were used. The rats were individually
housed in plastic cages and maintained under an artifi-
cial 12 h/12 h light/dark cycle (lights on 09:00 to 21:00)
at 23 ± 1 °C and 50 ± 10 % humidity. The rats had ad
libitum access to food and water. All of the experiments
were conducted in accordance with the European
Community guidelines for the use of experimental ani-
mals and approved by the Peking University Committee
on Animal Care and Use.Surgery
Surgical procedure details were described previously
[40]. The animals were implanted chronically with stain-
less steel screws over the frontal-parietal cortex and a
pair of wire electrodes through the nuchal muscles for
recording of electroencephalogram (EEG) and electro-
myogram (EMG), respectively. Additionally, a guide can-
nula (26 gauge) was implanted 1 mm above the DRN at
coordinates, AP = −8.0; L = 0.0 and DV = −5.8 [41].
Drugs and drug administration
CaCl2 was purchased from Sigma-Aldrich (Louis, MO,
USA). CaCl2 was dissolved in saline and the pH of the
solution was adjusted to 7.3. CaCl2 was microinjected
into the DRN at 09:00. CaCl2 or saline was injected into
the rat DRN with an injection cannula (29 gauge), which
extended 1 mm beyond the guide, in a 0.2 μl volume
over a 2 min period. Histological verification of cannula/
injection sites was carried out at the end of the experi-
ments. All the data presented in the present study are
derived from animals whose injection site was within the
limits of DRN. The location of cannula/injection is
shown in Additional file 1: Figure S1 online.
EEG and EMG recordings and analysis
For the electrophysiological recordings, all of the rats
were placed in an electrically shielded box in a noise-
attenuated environment with a light-weight shielded
cable plugged into the connector on the rat’s head and
attached to a counterbalanced swivel. The signals were
routed to an electroencephalograph (model MP 150,
BIOPAC Systems, CA, USA).
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09:00, immediately after CaCl2 or vehicle intra-DRN
application. The signals were amplified and filtered
(EEG, 0.5-30 Hz; EMG, 10–100 Hz) and then digi-
tized at a sampling rate of 128 Hz and recorded
using AcqKnowledge software (BIOPAC Systems). The
EEG/EMG recordings were analyzed using SleepSign
2.0 software (Kissei, Japan), with the following criteria:
W (low-amplitude EEG activity and high-voltage
EMG activity), REMS (Fast-fourier transform [FFT]
theta ratio of EEG ≥ 60 %, desynchronized EEG, ab-
sence of tonic EMG, and occasional body twitches
while maintaining a recumbent sleep posture), SWS
(FFT delta ratio of EEG ≥ 70 %, large-amplitude, syn-
chronous EEG with sleep spindles present, greatly di-
minished tonic EMG, eyes closed, small eye movement
potentials, and recumbent posture), and LS (FFT delta ra-
tio of EEG < 70 %, high-amplitude slow or spindle EEG ac-
tivity, and low-amplitude EMG activity). As a final step,
the defined sleep-wake stages were examined and cor-
rected according to the visual observation of the animal
which was recorded by video camera. NREMS time was
equal to SWS time + LS time. TS time was equal to
NREMS time + REMS time.
High-performance liquid chromatography with
electrochemical detection
The rats were decapitated 3 h after CaCl2 intra-DRN ad-
ministration (12:00). The DRN, LC, hypothalamus, and
prefrontal cortex were dissected and extracted with
0.2 M perchloric acid by ultrasonic homogenation.
Details of the neurotransmitter analysis procedure
were described previously [42]. High-performance li-
quid chromatography with electrochemical detection
(HPLC-ECD) was used to determine NE, 5-HT and 5-
HIAA levels under the following conditions: flow rate
(0.60 ml/min), temperature (40 °C), column (Shiseido
Capcell Pak C18 MG F90816 column; 3.0 mm inner
diameter, 75 mm length, 3 μm pore size), injection
volume (20 μl partial loop), mobile phase (0.1 M
NaH2PO4, 0.85 mM OSA, 0.05 mM Na2EDTA, 11 %
CH3OH, pH 3.25 with H3PO4), detector and conditions
(analytical cell: 5011A, E1 = − 175 mV, E2 = + 200 mV;
guard cell: 5020, EGC = + 250 mV).
Immunohistochemistry
The rats were sacrificed 3 h after CaCl2 intra-DRN ad-
ministration (12:00). Under deep anesthesia with chloral
hydrate (300 mg/kg, i.p.), the rats were first perfused
with 500 ml of 4 % paraformaldehyde. Whole brains
were immediately removed and postfixed in the same
fixative at 4 °C for 24 h, and then immersed in 30 % su-
crose at 4 °C for cryoprotection. The brains were rapidly
frozen on liquid n-hexane that was cooled with amixture of solid carbon dioxide and ethanol. Coronal
sections that encompassed the VLPO (bregma −0.4 mm
~ −0.8 mm), Pef (bregma −2.8 mm~ −3.4 mm), TMN
(bregma −3.8 mm~ −4.3 mm), DRN (bregma −7.6 mm
~ −8.3 mm) and LC (bregma −9.7 mm~ −10.2 mm) [41]
were freeze-cut into 20 μm thicknesses with a cryo-
stat (Leica CM1850, Leica Microsystems UK, Milton
Keynes, UK).
Each section was immunostained both for nucleus-
specific neurotransmitter marker (Additional file 1: Table)
and c-Fos. Sections were washed in PBS (3 × 5 min), then
incubated in cold acetone for 30 min, followed by washing
in PBS (3 × 5 min). Antigen retrieval was conducted in
citrate buffer (pH = 6.0) via microwave. After sections
returned to room temperature naturally, sections were
immersed in PBS containing 5 % donkey non-specific
serum and 0.3 % Triton X-100 for 30 min. Sections were
incubated in the appropriate primary antibodies for spe-
cific neurotransmitter markers and c-Fos diluted in PBS
containing 1.5 % donkey non-specific serum, 0.3 % Triton
X-100 for 12–16 h at 4 °C. After washing in PBS
(3 × 5 min), sections were incubated with fluorophore-
conjugated donkey anti-rabbit/goat/mouse immuno-
globulin G (secondary antibodies) for 120 min at
room temperature, washed 3 × 5 min in PBS. At last,
the sections were mounted with fluorescent mounting
medium with 4′,6-diamidino-2-phenylindole (DAPI).
Details of antibodies are summarized in Additional
file 1: Table S1 online.
The sections were examined in a confocal microscope
(TCS SP8, Leica). Confocal images were processed using
Leica LAS AF. The brightness and contrast of captured
images were adjusted in Photoshop (Adobe Systems).
The nucleus-specific neurotransmitter markers were la-
beled by green, c-Fos was labeled by red and DAPI was
labeled by blue.
In each section, c-Fos positive ratio was counted (the
number of c-Fos [+]-nucleus-specific neurotransmitter
marker [+] cells divided by the number c-Fos [±]-nucleus-
specific neurotransmitter marker [+] cells and then
multiply 100 %). Immunoreactive nuclei were counted bi-
laterally (except for DRN) using at least three serial sec-
tions for each area, data were then averaged in order to
produce the mean of each group.
Statistical analysis
The data were analyzed using SPSS 17.0 software and
are expressed as mean ± SEM. Multiple comparisons
data were analyzed using one-way analysis of variance
(ANOVA) followed by the Student-Newman-Keuls post
hoc test. Pearson’s correlation analysis was performed on
pooled data, from both controls and CaCl2-treated rats.
In all of the tests, p < 0.05 was considered statistically
significant.
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Additional file 1: Figure S1. Photomicrographs of representative
cannula placements in dorsal raphe nucleus (DRN). (a) Sections are
according to Paxinos and Watson [41]; (b) Nissle staining in DRN section.
Table S1. Details of antibody. Table S2. Effects of CaCl2 microinjection in
the DRN on sleep parameters (raw data 1). Table S3. Effects of CaCl2
microinjection in the DRN on sleep parameters (raw data 2). Table S4.
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